Cargando…
Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose
With the spread of the new SARS-CoV-2 variants, many countries have begun COVID-19 vaccine booster programs with the mix-and-match strategy. However, research on the adverse events (AE) of booster doses is still scarce. The aim of our study was to analyze the reported incidence rate (IR), and factor...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316082/ https://www.ncbi.nlm.nih.gov/pubmed/35891279 http://dx.doi.org/10.3390/vaccines10071115 |
_version_ | 1784754718080237568 |
---|---|
author | Chen, Po-Yu Wu, Bih-Ju Su, Mei-Chin Lin, Yen-Hsi Chiang, Shu-Chiung Wu, Jau-Ching Chen, Tzeng-Ji Chen, Yu-Chun |
author_facet | Chen, Po-Yu Wu, Bih-Ju Su, Mei-Chin Lin, Yen-Hsi Chiang, Shu-Chiung Wu, Jau-Ching Chen, Tzeng-Ji Chen, Yu-Chun |
author_sort | Chen, Po-Yu |
collection | PubMed |
description | With the spread of the new SARS-CoV-2 variants, many countries have begun COVID-19 vaccine booster programs with the mix-and-match strategy. However, research on the adverse events (AE) of booster doses is still scarce. The aim of our study was to analyze the reported incidence rate (IR), and factors associated with AE, including short-term serious adverse events (SAE) and short-term non-serious adverse events (NSAE), among different vaccine products through the hospital-based Vaccine Adverse Event Reporting System (VAERS). A total of 7432 records were collected during the three-month study period. While more than half of the responses (52.2%) reported the presence of AE after receiving a booster dose, only a few AE were considered SAE (2.4%). AE were significantly higher among women and people of younger age, and the brand of vaccines is the strongest factor associated with post-booster dose AE. The incidence of AE in mRNA1273 is higher than in BNT162b2 and MVC-COV1901 (IRR mRNA1273 vs. BNT162b2: 1.22, 95% CI: 1.11–1.34; BNT162b2 vs. MVC-COV1901: 2.77, 95% CI: 2.27–3.39). The IR of different groups were calculated to support the decision making of the booster vaccine. Although AE were not uncommon for booster vaccines, almost all AE were not serious and predictable using estimated IR. This result can be used to optimize booster vaccine decision making. |
format | Online Article Text |
id | pubmed-9316082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93160822022-07-27 Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose Chen, Po-Yu Wu, Bih-Ju Su, Mei-Chin Lin, Yen-Hsi Chiang, Shu-Chiung Wu, Jau-Ching Chen, Tzeng-Ji Chen, Yu-Chun Vaccines (Basel) Article With the spread of the new SARS-CoV-2 variants, many countries have begun COVID-19 vaccine booster programs with the mix-and-match strategy. However, research on the adverse events (AE) of booster doses is still scarce. The aim of our study was to analyze the reported incidence rate (IR), and factors associated with AE, including short-term serious adverse events (SAE) and short-term non-serious adverse events (NSAE), among different vaccine products through the hospital-based Vaccine Adverse Event Reporting System (VAERS). A total of 7432 records were collected during the three-month study period. While more than half of the responses (52.2%) reported the presence of AE after receiving a booster dose, only a few AE were considered SAE (2.4%). AE were significantly higher among women and people of younger age, and the brand of vaccines is the strongest factor associated with post-booster dose AE. The incidence of AE in mRNA1273 is higher than in BNT162b2 and MVC-COV1901 (IRR mRNA1273 vs. BNT162b2: 1.22, 95% CI: 1.11–1.34; BNT162b2 vs. MVC-COV1901: 2.77, 95% CI: 2.27–3.39). The IR of different groups were calculated to support the decision making of the booster vaccine. Although AE were not uncommon for booster vaccines, almost all AE were not serious and predictable using estimated IR. This result can be used to optimize booster vaccine decision making. MDPI 2022-07-13 /pmc/articles/PMC9316082/ /pubmed/35891279 http://dx.doi.org/10.3390/vaccines10071115 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Po-Yu Wu, Bih-Ju Su, Mei-Chin Lin, Yen-Hsi Chiang, Shu-Chiung Wu, Jau-Ching Chen, Tzeng-Ji Chen, Yu-Chun Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose |
title | Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose |
title_full | Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose |
title_fullStr | Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose |
title_full_unstemmed | Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose |
title_short | Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose |
title_sort | risk factors and incidence rates of self-reported short-term adverse events of covid-19 vaccine booster dose |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316082/ https://www.ncbi.nlm.nih.gov/pubmed/35891279 http://dx.doi.org/10.3390/vaccines10071115 |
work_keys_str_mv | AT chenpoyu riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT wubihju riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT sumeichin riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT linyenhsi riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT chiangshuchiung riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT wujauching riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT chentzengji riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose AT chenyuchun riskfactorsandincidenceratesofselfreportedshorttermadverseeventsofcovid19vaccineboosterdose |